Full Year 2023 Investor Presentation
13
Investor presentation
Full year 2023
Financial results - Full year of 2023
Novo NordiskⓇ
Change
Change
2023
2022
In DKK million
Sales
Gross profit
Gross margin
(reported)
(CER)
232,261
196,496
176,954
31%
36%
148,506
32%
37%
84.6%
83.9%
Sales and distribution costs
(56,743)
(46,217)
23%
26%
Percentage of sales
24.4%
26.1%
Research and development costs
(32,443)
(24,047)
35%
37%
Percentage of sales
Administration costs
Percentage of sales
14.0%
(4,855)
2.1%
13.6%
(4,467)
9%
11%
2.5%
Other operating income and expenses
119
1,034
(88%)
(88%)
Operating profit
102,574
74,809
37%
44%
Operating margin
44.2%
42.3%
Financial items (net)
2,100
(5,747)
Profit before income tax
104,674
69,062
52%
Income taxes
(20,991)
(13,537)
55%
Effective tax rate
20.1%
19.6%
Net profit
83,683
55,525
51%
Diluted earnings per share (DKK)
18.62
12.22
52%
CER: Constant exchange ratesView entire presentation